Form 4: Madrigal Pharmaceuticals Director Exercises Options and Sells Shares Under Pre-Arranged Plan

A director at Madrigal Pharmaceuticals, Paul A. Friedman, exercised stock options and subsequently sold 1,400 shares of common stock for a significant profit, as part of a pre-arranged trading plan.

Summary

• Paul A. Friedman, a Director of Madrigal Pharmaceuticals, Inc. (MDGL), engaged in transactions involving the company's common stock.
• On July 18, 2025, Friedman acquired 1,400 shares of common stock by exercising stock options at a price of $9.45 per share. These options were fully vested and exercisable.
• On the same date, Friedman sold 1,400 shares of common stock at a weighted average price of $350.0314 per share, with individual sales ranging from $350.00 to $350.19.
• These sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on March 14, 2025.
• Following these transactions, Friedman's direct beneficial ownership of common stock decreased by 1,400 shares, from 188,564 to 187,164 shares.
• Friedman also indirectly beneficially owns 655,540 shares through SQN LLC, where he and his spouse are managing members, though he disclaims beneficial ownership except for his pecuniary interest.
• The exercise of options and subsequent sale resulted in an estimated profit of approximately $476,814 for the 1,400 shares.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine insider sale under a pre-arranged plan, which is common for executives and directors to manage personal finances and diversify holdings. While it reduces insider ownership, the pre-planned nature mitigates negative sentiment.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new, negative information.
• The significant difference between the option exercise price ($9.45) and the sale price ($350.0314) highlights the substantial value creation for the option holder.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces insider ownership.
• The net reduction of 1,400 shares in direct beneficial ownership by a director.

Future Outlook

NA

Industry Context

This is a routine insider transaction for a pharmaceutical company, reflecting a director's personal financial management rather than a specific industry trend or competitive development.

Related Party Transactions

• Paul A. Friedman and his spouse are managing members of SQN, LLC, which indirectly holds 655,540 shares of Madrigal Pharmaceuticals common stock. Friedman disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: A director's sale, even if pre-planned, slightly reduces insider alignment, but the pre-planned nature minimizes concerns about negative signals. The significant profit from options exercise demonstrates value creation for long-term equity holders.

Key Dates

Recommendation

The filing details a routine insider transaction (option exercise and sale) executed under a pre-arranged 10b5-1 plan. This type of transaction is common for directors managing personal liquidity and diversification, and it does not typically signal a change in the company's fundamental outlook or performance. While it slightly reduces direct insider ownership, the pre-planned nature mitigates any negative market interpretation. Therefore, the filing itself does not provide new information that would warrant a change in investment thesis, leading to a 'hold' recommendation based solely on this specific Form 4.

Keywords

Madrigal Pharmaceuticals, MDGL, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Director Transactions, Beneficial Ownership